1100 WINTER STREET, WALTHAM, MA
Director Resignation and Election at Kalaris Therapeutics
Kalaris Therapeutics Elects New Class III Directors at Annual Meeting
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
CFO Resignation - Matthew Gall Steps Down at Kalaris Therapeutics
Reports Full Year 2025 Financial Results and Provides Business Updates
Investor Presentation
Announces Oversubscribed $50.0 Million Private Placement
Q1
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
SEC Staff Correspondence
Correspondence
Submission Upload